Wednesday, July 8, 2026

Patent intelligence · US

US 9351964

Methods for treating cancer and non-neoplastic conditions

granted A61KA61K31/437A61K31/44A61K31/4745
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 10
Applicant portfolio 149
Patent details — US 9351964
Jurisdiction
US
Status
granted
Grant date
May 31, 2016
Expiration
May 26, 2036
Claims
6
CPC classes
A61K, A61K31/437, A61K31/44, A61K31/4745
View on Google Patents ↗

Quick answer

US 9351964 (Methods for treating cancer and non-neoplastic conditions) is held by PTC THERAPEUTICS, INC.. Status: granted. Granted May 31, 2016. Expires May 26, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
6
CPC classes
A61K, A61K31/437, A61K31/44, A61K31/4745, A61K45/06, A61P

More from PTC THERAPEUTICS, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12398140

    Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia

    PTC THERAPEUTICS, INC. · Expires Aug 21, 2045

    granted
  2. US 12384789

    Compounds for treating Huntington's disease

    PTC THERAPEUTICS, INC. · Expires Aug 7, 2045

    granted
  3. US 12384797

    Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia

    PTC THERAPEUTICS, INC. · Expires Aug 7, 2045

    granted
  4. US 12281083

    2-substituted amino-naphth (1,2-d) imidazol-5-one compounds of pharmaceutically acceptable salts thereof

    PTC THERAPEUTICS, INC. · Expires Apr 17, 2045

    granted
  5. US 12139499

    Heteroaryl compounds for treating Huntington's disease

    PTC THERAPEUTICS, INC. · Expires Nov 7, 2044

    granted
  6. US 12103926

    Compounds for treating huntington's disease

    PTC THERAPEUTICS, INC. · Expires Sep 26, 2044

    granted
  7. US 12023335

    Method for treating pancreatic cancer

    PTC THERAPEUTICS, INC. · Expires Jun 27, 2044

    granted
  8. US 11938101

    Polymorphic forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide

    PTC THERAPEUTICS, INC. · Expires Mar 21, 2044

    granted

Frequently asked questions

What is US patent 9351964?

US 9351964 (Methods for treating cancer and non-neoplastic conditions) is held by PTC THERAPEUTICS, INC.. Status: granted. Granted May 31, 2016. Expires May 26, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9351964?

PTC THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 149 pharmaceutical patents for this assignee.

When does US 9351964 expire?

Our index shows an expiration date of May 26, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.